Earnings play on HIMS – GLP-1 expansion timing, breakout chart, and volume momentum into May 6

This is a straight earnings play write-up — Just a thesis I’ve built based on timing, catalyst behavior, and chart structure.

# What’s the setup?

**Earnings are Monday, May 6 (after hours).**
The trade is built around that event using short-dated options (May 9 expiry).

# Key points:

**1. Timed GLP-1 headline**
On April 29, HIMS announced entry into compounded semaglutide (a weight-loss drug space growing rapidly). That announcement came **right before earnings** — companies don’t do that unless they plan to build on it during the call.

**2. Technical structure**
The stock has broken out of multi-month consolidation, with price moving steadily on increasing volume. Bid/ask has stayed clean. No signs of topping or blow-off behavior yet.

**3. Momentum into earnings**
Options volume and open interest are building, but volatility isn’t yet extreme. You can still enter at reasonable premiums if you're betting on a strong earnings reaction.

**4. Thesis: If they beat and lean into GLP-1 demand, the stock could re-rate higher — especially with low float and strong engagement.**

# Risks:

* If earnings underdeliver or guidance is vague, the stock could fade fast
* IV crush is likely, so this isn’t a trade to hold post-call without direction
* GLP-1 adoption might be seen as too early to model into valuation

**My position:**
$20K in May 9 calls across $35C / $37.5C / $40C strikes...not financial advice...